- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01754181
Initial Testing of the Diabeloop Algorithm in T1D Patients on Pump Therapy Over the Prandial Period and Physical Activity. (DiabeloopWP6-0)
Development of the Glycemic Control Algorithm, in Prandial and Physical Effort Situations.
The main objective is to assess if the Diabeloop algorithm provides better glycemic control than a "manual" usual algorithm of patients with type 1 diabetes treated by insulin pump during meals, and during activity qualified "moderate" to "severe" by the patients.
The study will be conducted in 18 patients. The investigation centers are: CHSF (for Diabeloop algorithm test during activity), CHU of Grenoble and CHU of Toulouse (for Diabeloop algorithm test during meals.
Panoramica dello studio
Descrizione dettagliata
Grenoble and Toulouse will test the prandial algorithm with several carbohydrate intake and a primer of 50% or 75% of the total bolus. Groups of patients are described as follows:
- Group I: patients have a meal with the usual carbohydrate intake. The meal bolus is made according to the current treatment.
- Group II: patients have a meal with a "low" carbohydrate intake (50% reduction of carbohydrate).
- Group III: patients have a meal with a "strong" carbohydrate intake (increase 50% of carbohydrate).
- Group IV: patients of group IV have each meal with carbohydrate intake but their usual bolus will be omitted.
- Inclusion visit V1: The study will be proposed at the patients who meet the inclusion criteria. After signing the consent, the investigator shall designate one group for each patient.
- Visit V2 (24 hours before the visit V3): Installation, calibration and education of two glucose sensors dexcom G4 ™ will be performed by a nurse. The patient will keep two sensors until the end of the study (end of V4).
- Visit V3 (algorithm test): Patient will be fitted with its insulin pump and the two sensors dexcom G4 ™. These will be coupled by the engineer LETI to the computer on which is installed the control algorithm to be tested. Lunch will be taken at 1 pm. The algorithm will provide proposals insulin every 15 minutes until 6 pm.
- Visit V4 (patient control): Patient will be fitted with two sensors dexcom G4 ™ and its insulin pump programmed according to the usual algorithm. The meal will be taken at 1h PM. Patient can leave the site at 6 pm after removal of sensors.
CHSF (Centre Hospitalier Sud Francilien) will test the algorithm glycemic control during physical activity of moderate (50% VO2max) or high intensity (75% VO2max) for 30 minutes on a bicycle ergometer. In different situations, three patient groups will be created:
- Group A: Patients practice an "average" physical activity(50% VO2max) with usual temporary basal reduction (usually 50% of reduction during the test and 2h next).
- Group B: Patients practice an "intense" physical activity (75% VO2max) with usual temporary basal reduction (usually 80% of reduction during the test and 2h after).
- Group C: patients practice an "average" physical activity (50% VO2max) but without concomitant reduction of temporary basal.
- Inclusion visit V1 : The study will be proposed at the patients who meet the inclusion criteria. After signing the consent, the investigator shall designate one group for each patient.
- Visit V2 : Patient will be equipped with two sensors dexcom G4 ™ and a heart rate monitor. Calibrated meal is expected at 11h 30 pm. The patient will be administered his insulin dose according to his usual algorithm. The physical test will begin three hours after the meal. It will be carried on bicycle ergometer for 30 minutes at an medium or high intensity. (Average = 50% VO2max, or high level = 75% VO2max).
- Visit V3: The same test is repeated for each patient during this visit. Its insulin pump will be controlled by the doses proposal of the algorithm after manual validation by the investigator. These will continue until the next morning, and the patient will spend overnight in the hospital.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Evry, Francia, 91058
- Centre Hospitalier Sud Francilien
-
Grenoble, Francia, 38043
- University hospital of Grenoble
-
Toulouse, Francia, 31403
- University Hospital of Toulouse
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients with type 1 diabetes treated by external insulin pump;
- Patients with HbA1c <8.5%.
- Patients aged 18 years or less;
- Patient who signed consent;
- Patient affiliated with Social Security.
For Grenoble and Toulouse Centers (Prandial algorithm test : MEAL):
- Patient is practicing functional insulin therapy is a fixed meal plan.
For CHSF center (test of algorithm during activity):
- Patient able to perform moderate or intense activity during 30 minutes.
Exclusion Criteria:
- Patients with type 2 diabetes
- All serious diseases that could interfere with the study
- Insulin resistance and obesity (BMI> 30 kg/m2 and / or insulin requirements> 2 U / kg / day)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Proposed treatment by Diabeloop algorithm
the insulin dose is calculated by the algorithm based on the usual treatment of the patient, the ratio I / C, the intensity of physical activity and blood glucose sensor.
|
the intervention is applied only at the dose of insulin
|
Nessun intervento: usual treatment
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Time spent in glucose reference intervals
Lasso di tempo: After the end of the tests
|
After the end of the tests
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Measuring glucose sensor 2h, 3h and 4h post-prandial and AUC, in every situation tested to evaluate the efficacy and safety (time spent in hypoglycemia)
Lasso di tempo: After the end of the tests
|
To evaluate the efficacy and safety of prandial algorithm, informed carbohydrate intake by the patient either quantitatively or semi-quantitative, or not informed way.
|
After the end of the tests
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Comparison of glucose sensor 2h, 3h and 4h post-prandial and AUC in conditions identical meals for each trigger level (50 or 75%). Measuring AUC during and 2 hours after physical activity, then to lunch time, during dinner and throughout the night.
Lasso di tempo: After the end of the tests
|
|
After the end of the tests
|
Collaboratori e investigatori
Investigatori
- Cattedra di studio: Guillaume CHARPENTIER, MD, Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
- Investigatore principale: Sylvia Franc, MD, Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
- Investigatore principale: Pierre-Yves BENHAMOU, Pr., CHU of Grenoble
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2012-A01489-34
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Diabete di tipo 1
-
AmgenCompletato
-
Paolo MilaniReclutamentoAmiloidosi | Amiloidosi cardiaca | ATTR Amiloidosi Wild TypeItalia
-
Steen Hvitfeldt PoulsenReclutamentoATTR Amiloidosi Wild TypeDanimarca
-
Oncology Institute of Southern SwitzerlandUniversity of Kiel; Ente Ospedaliero Cantonale, BellinzonaCompletato
-
AmgenCompletatoCancro colorettale metastatico RAS wild-type
-
Henan Cancer HospitalCompletatoCancro colorettale metastatico KRAS, NRAS e BRAF V600E wild-type
-
Austin Neuromuscular CenterAlnylam PharmaceuticalsReclutamentoPolineuropatie | Amiloidosi da transtiretina | Amiloidosi correlata alla transtiretina di tipo selvaggio (ATTR). | Amiloidosi cardiaca da transtiretina wild-type | Amiloidosi ATTR di tipo selvaggioStati Uniti
-
Denver Health and Hospital AuthorityIscrizione su invitoDisturbo evitante restrittivo dell'assunzione di cibo | Anoressia Nervosa, Binge Eating/Purging Type | ARFIDE | Tipo restrittivo di anoressia nervosaStati Uniti
-
Rosemary Claire RodenChildren's Miracle NetworkIscrizione su invitoBulimia nervosa | Comportamento impulsivo | Eliminazione (disturbi alimentari) | Problemi alimentari | Disturbi alimentari in adolescenza | Anoressia Nervosa/Bulimia | Anoressia in adolescenza | Anoressia Nervosa, Atipica | Anoressia Nervosa, Binge Eating/Purging TypeStati Uniti
-
Oxford Brookes UniversityUniversity of OxfordCompletatoAttività fisica | Salute mentale Benessere 1 | Funzione cognitiva 1, sociale | Academic Attainment | Fitness TestingRegno Unito
Prove cliniche su Insulin
-
Michigan State UniversityCompletatoEsercizio | InsulinaStati Uniti
-
University of Colorado, DenverCompletatoDiabete di tipo 1Stati Uniti
-
Julphar Gulf Pharmaceutical IndustriesParexel; Profil Institut für Stoffwechselforschung GmbHCompletatoDiabete mellitoGermania
-
Universiti Sains MalaysiaCompletato
-
Amphastar Pharmaceuticals, Inc.Completato
-
Sheffield Teaching Hospitals NHS Foundation TrustKing's College Hospital NHS Trust; Cambridge University Hospitals NHS Foundation... e altri collaboratoriCompletatoDiabete di tipo 1Regno Unito